logoTry Persana

CellChorus - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about CellChorus including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

CellChorus company logo

The dynamic single-cell analysis company™

CellChorus® applies visual AI to evaluate thousands of microscopy experiments in parallel to improve the development and delivery of novel therapies for biopharmaceutical and research customers.

HeadquartersHouston, US
Team size11-50
FoundedNA

What is CellChorus? - Company Overview & Details

CellChorus is CellChorus® applies visual AI to evaluate thousands of microscopy experiments in parallel to improve the development and delivery of novel therapies for biopharmaceutical and research customers., the company is headquartered in Houston, US.

Who Founded CellChorus?

CellChorus was founded by Navin Varadarajan, Daniel Meyer.

Who are the Key Executives at CellChorus? - Leadership Team

CellChorus is led by experienced executives in key positions:

Chief Executive Officer (CEO) of CellChorus

Daniel MeyerCEO

Chief Technology Officer (CTO) of CellChorus

Rebecca BerdeauxCTO

About Daniel Meyer - CEO of CellChorus

Daniel Meyer serves as the Chief Executive Officer of CellChorus, leading the company's strategic vision and operations. Connect with them on LinkedIn for professional insights.

CellChorus Company Details & Key Information

Where is CellChorus located?

CellChorus is headquartered in Houston, US.

How many employees does CellChorus have?

CellChorus has 11-50 employees.

CellChorus Official Website

How much funding has CellChorus raised?

CellChorus has raised $2.3 Million across 11 funding rounds. The most recent funding was completed on 2024-06-02.

Funding Overview

CellChorus received a $2.5 million grant from NCATS to advance its TIMING platform for cell therapy applications.

$2.3 Million
Total Funding Raised
11
Funding Rounds
2024-06-02
Latest Round

CellChorus Funding History

Grant
2024-06-02
$2.3 Million
Grant
2023-07-21
$2 Million

Who are the key investors in CellChorus?

CellChorus is backed by 2 key investors including National Institute of General Medical Science, NCATS. These investors focus on Biotechnology, Medical Research, Translational Science sectors.

CellChorus Investor Overview

2
Key Investors
3
Focus Areas
1
Notable Investments

Complete List of CellChorus Investors

National Institute of General Medical Science

Government agency focused on biomedical research.

Investment Focus
Biotechnology
Medical Research
Notable Portfolio Companies
$2.3 Million in grants

NCATS

National Center for Advancing Translational Sciences.

Investment Focus
Translational Science
Biotechnology

What sectors do CellChorus investors focus on?

The investors backing CellChorus primarily focus on Biotechnology, Medical Research, Translational Science sectors.

Biotechnology
Medical Research
Translational Science

Featured Investor: National Institute of General Medical Science

National Institute of General Medical Science

Government agency focused on biomedical research.

Notable Investments: $2.3 Million in grants

What are CellChorus's future plans?

CellChorus CellChorus aims to expand its TIMING platform capabilities and enhance partnerships in biotechnology.

CellChorus Strategic Outlook

Strategic Focus
Defined
0
Key Challenges
2
Growth Opportunities

What opportunities does CellChorus have?

CellChorus has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for CellChorus

1

Expansion of TIMING platform applications

2

New collaborations in immunotherapy

CellChorus Strategic Position Summary

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about CellChorus?

CellChorus has 2 recent news updates covering key business developments and market activities.

CellChorus News Overview

2
Recent Articles
Active
Media Coverage
2024-05-28
Latest Update

What is CellChorus in the news for?

CellChorus is currently featured in news for CellChorus Inc. is developing AI-powered TIMING platform. and other significant business developments.

Recent News Articles About CellChorus

Article 1
2024-05-28

CellChorus Inc. is developing AI-powered TIMING platform.

CellChorus is advancing the TIMING platform to enhance T-cell therapies in cancer treatment.

news-medical.net
Read News
Article 2
2023-11-27

CellChorus Inc. hired Andrew Last as board of directors on Nov 28th '23.

CellChorus appoints Andrew Last, PhD, to its board of directors to enhance growth of the TIMING platform.

biospace.com
Read News

CellChorus FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about CellChorus including information about founders, CEO, funding history, investors, headquarters location, and company details. 17 frequently asked questions covering key information about the company.

CellChorus Questions & Answers - Company Information

Q1

What is CellChorus?

CellChorus® applies visual AI to evaluate thousands of microscopy experiments in parallel to improve the development and delivery of novel therapies for biopharmaceutical and research customers.

Q2

Who founded CellChorus?

CellChorus was founded by Navin Varadarajan, Daniel Meyer.

Q3

Who is the CEO of CellChorus?

The CEO of CellChorus is Daniel Meyer. You can find more information about them on their LinkedIn profile.

Q4

How much funding has CellChorus raised?

CellChorus has raised a total of $$2.3 Million across 11 funding rounds. The most recent funding was completed on 2024-06-02.

Q5

Who are the investors in CellChorus?

CellChorus's key investors include National Institute of General Medical Science, NCATS.

Q6

Where is CellChorus headquartered?

CellChorus is headquartered in Houston, US.

Q7

How many employees does CellChorus have?

CellChorus has 11-50 employees.

Q8

What is CellChorus's official website?

You can visit CellChorus's official website at https://cellchorus.com.

Q9

What was CellChorus's latest funding round?

CellChorus's latest funding round was a Grant round of $$2.3 Million completed on 2024-06-02.

Q10

Who is founder?

Daniel Meyer

Q11

Who is cto?

Rebecca Berdeaux

Q12

What does the company do?

CellChorus® applies visual AI to evaluate thousands of microscopy experiments for developing new therapies.

Q13

How much funding?

$2.3 Million

Q14

Latest funding date?

2024-06-02

Q15

Who are the investors?

National Institute of General Medical Science NCATS

Q16

What are the opportunities?

Expansion of TIMING platform applications New collaborations in immunotherapy

Q17

Latest news?

CellChorus is advancing the TIMING platform to enhance T-cell therapies in cancer treatment. CellChorus appoints Andrew Last, PhD, to its board of directors to enhance growth of the TIMING platform.

More Information About CellChorus

For additional details about CellChorus, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.